Clinical Trials

Status
Published

1504 Results

Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases

Status Notes
Activation, Effective 9/23/2020, 2:00 pm eastern
Research Committee(s)
Melanoma
Activated
09-23-2020
ClinicalTrials.gov Registry Number
NCT04511013
Open
Phase
I-II
Accrual
0%
SWOG Clinical Trial Number
S1905

A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)

Status Notes
This study is open to accrual effective August 17, 2020 at 12:00 p.m. Pacific.
Research Committee(s)
Leukemia
Lymphoma
Activated
08-17-2020
ClinicalTrials.gov Registry Number
NCT#04315324
Open
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Research Committee(s)
Lung Cancer
Activated
08-17-2020
ClinicalTrials.gov Registry Number
NCT04402788
Open
SWOG Clinical Trial Number
CTSU/A021806

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Status Notes
This study is active in SWOG as of July 1, 2020.
Research Committee(s)
Gastrointestinal Cancer
Activated
07-01-2020
Open
SWOG Clinical Trial Number
CTSU/A081801

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Research Committee(s)
Lung Cancer
Activated
06-23-2020
ClinicalTrials.gov Registry Number
NCT04267848
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S1933

A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status

Status Notes
This study is open to accrual effective June 15, 2020 at 12:00 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
ClinicalTrials.gov Registry Number
NCT04310020
Open
Phase
II
Accrual
9%
SWOG Clinical Trial Number
S1929

Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC)

Status Notes
S1929 will open to accrual June 15, 2020, effective 12:00 pm PST.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
ClinicalTrials.gov Registry Number
04334941
Open
SWOG Clinical Trial Number
CTSU/A151804

ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS

Status Notes
This study is active in SWOG as of June 15, 2020.
Research Committee(s)
Immunomolecular Therapeutics
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Leukemia
Lung Cancer
Lymphoma
Melanoma
Myeloma
Early Therapeutics & Rare Cancers
Activated
06-15-2020
Open
Accrual
3%
SWOG Clinical Trial Number
S1823

A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors

Research Committee(s)
Prevention & Epidemiology
Genitourinary Cancer
Activated
06-01-2020
Open
SWOG Clinical Trial Number
CTSU/EA5181
Open
Phase
III
Accrual
1%
SWOG Clinical Trial Number
S1914

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC

Status Notes
This study is open to accrual effective March 25, 2020.
Research Committee(s)
Lung Cancer
Activated
03-25-2020
ClinicalTrials.gov Registry Number
04214262
Open
Phase
II
Accrual
4%
SWOG Clinical Trial Number
S1900B

A PHASE II STUDY OF SELPERCATINIB (LOXO-292) IN PATIENTS WITH RET FUSION-POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)

Status Notes
S1900B will open to accrual February 10, 2020, effective 12:00 pm PST.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
02-10-2020
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-GY020

A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

Research Committee(s)
Early Therapeutics & Rare Cancers
Gynecologic Cancer
Activated
02-07-2020
ClinicalTrials.gov Registry Number
04214067
Open
Accrual
100%
SWOG Clinical Trial Number
S1900C

A PHASE II STUDY OF TALAZOPARIB PLUS AVELUMAB IN PATIENTS WITH STAGE IV OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER BEARING PATHOGENIC STK11 GENOMIC ALTERATIONS (LUNG-MAP SUB-STUDY)

Status Notes
S1900C will open to accrual January 16, 2020, effective 2:00 pm PST.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
01-16-2020
Open
Phase
III
Accrual
3%
SWOG Clinical Trial Number
S1827

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Status Notes
This study is open to accrual effective January 10, 2020 at 2:00 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
01-10-2020
ClinicalTrials.gov Registry Number
04155034
Open
Phase
II
Accrual
4%
SWOG Clinical Trial Number
S1922

Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Status Notes
The study referenced above is open for participation effective Monday, December 16, 2019 at 2:00 p.m. Eastern.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-16-2019